ReviewNature reviews. Molecular cell biology2024
CRISPR technologies for genome, epigenome and transcriptome editing.
Review in Nature reviews. Molecular cell biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 146 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
146 citing papers in PubMed, 183 citations in OpenAlex.
- From signals to systems: the epigenetic-microbiome-mitochondrial axis in IBD pathogenesis.Gut microbes · 2026Review
- In vivo immune cell engineering from bench to clinical reality.Pharmaceutical science advances · 2026Review
- LipReg4 deletion blocks hypertension induced by gut S. aureofaciens Tü117.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Chromatin Modifications Orchestrate DNA Repair Pathway Choice: Epigenetics Strategies for Enhancing CRISPR-Cas9-Mediated Knock-In Efficiency.Cell proliferation · 2026Review
- Advances and Applications of Genome Editing in Precision Crop Breeding.Plants (Basel, Switzerland) · 2026Review
- Review
- Next-generation CAR-T cell therapy against cancer: precision engineering, programmable immunity, and emerging clinical frontiers.Journal of the Egyptian National Cancer Institute · 2026Review
- Lipid nanoparticles optimized for large RNA cargo and tissue targeting enhance in vivo genome editing.Nature biotechnology · 2026Article
- Technical limitations of CRISPR-Cas9 genome editing in bacteria: challenges and future directions.Archives of microbiology · 2026Review
- CRISPR-Cas9 genome editing: technological advances, delivery strategies and precision engineering of primary cells for therapeutic application in genetic disorders and diabetes mellitus.Molecular biology reports · 2026Review
- A noncontiguous code for RNA-guided DNA recognition at the origin of CRISPR-Cas.Science (New York, N.Y.) · 2026Article
- Long-Term Labeling and Differentiation Monitoring of Mouse Spermatogonial Stem Cells Using CellREADR.Biotech (Basel (Switzerland)) · 2026Article
- Strategies and mechanisms of precision genome engineering: From gene editing to genome writing.iMetaOmics · 2026Review
- Beyond Earth: Recent Advancements in Microgravity Biomedical and Genetic Research in Saudi Arabia.International journal of molecular sciences · 2026Review
- Identification and structure determination of a type III-Bv CRISPR complex that post-translationally modifies an associated toxin.Structure (London, England : 1993) · 2026Article
- Genetic influences on haematopoiesis.Nature reviews. Genetics · 2026Review
- Biotechnological Strategies for Cultured Poultry Meat Biofabrication Through Induced Pluripotent Stem Cell Reprogramming and CRISPR-Cas9-Mediated Genome Editing.Animals : an open access journal from MDPI · 2026Review
- Gene-Edited Stem Cells for Ischemic Vascular Disease: Current Advances and Future Perspectives.Current issues in molecular biology · 2026Review
- A One-Pot CRISPR-Cas12b Assay for Rapid Detection of Human Adenovirus Serotypes 3 and 7.Journal of medical virology · 2026Article
- Brain organoids and genome editing: A new era in understanding human brain development and disorders.Neural regeneration research · 2026Article
86 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our ability to edit genomes lags behind our capacity to sequence them, but the growing understanding of CRISPR biology and its application to genome, epigenome and transcriptome engineering is narrowing this gap. In this Review, we discuss recent developments of various CRISPR-based systems that can transiently or permanently modify the genome and the transcriptome. The discovery of further CRISPR enzymes and systems through functional metagenomics has meaningfully broadened the applicability of CRISPR-based editing. Engineered Cas variants offer diverse capabilities such as base editing, prime editing, gene insertion and gene regulation, thereby providing a panoply of tools for the scientific community. We highlight the strengths and weaknesses of current CRISPR tools, considering their efficiency, precision, specificity, reliance on cellular DNA repair mechanisms and their applications in both fundamental biology and therapeutics. Finally, we discuss ongoing clinical trials that illustrate the potential impact of CRISPR systems on human health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.